| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Dabigatran |
| Brand | Pradaxa® |
| Indication | For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. |
| Assessment Process | |
| NCPE assessment outcome | Full Pharmacoeconomic Evaluation Not Recommended |